Studies indicate that ingested oral cyanocobalamin tablets forever are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the yours liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during this first pass in its native forever form that it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health yours Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary lung functions forever were taken at days 45, 150 and 180 from baseline. yours Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels from Day 0 to Day 30.3

Jay M. Symptoms not very bad. Karl L. My congestion allergies did seem to get better after several days...Marsha R. I had forever some better days. Erin C. I believe it helped to a certain extent. William R. yours Improved after 3 days. Nancy C. On day 16 I felt so much better, by day 30 allergies continued to be improved. Angel C. Background of Cyanocobalamin Treatment in Allergic Disease MECHANISM OF ACTION: Vitamin B12 is essential to cell growth and cell division. B12 is the only known molecule in the human body uses with the element cobalt. The unique properties of cobalt permit a chemical reaction that produces the rungs of the forever DNA ladder. These rungs yours and forever are called nucleotides. yours For any human cell to divide, it must copy its own DNA. For this replication to occur, new rungs of the forever ladder must be provided with the help of B12.

With yours no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen forever period in Oregon, Washington and Idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior to the treatment in 1995 and yours one year later in 1996. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=27) had on average a greater reduction in IgE than the placebo group (n=34) for 13 out of 16 allergens.8

©2003 www.natural-breasts-enhancement.com All rights reserved.